<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Coactivation of platelets and the blood coagulation cascade contributes to the pathophysiology of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Combination therapy with antiplatelet and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> drugs may be needed for maximizing the prevention and treatment of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Few studies have thoroughly investigated the combined antithrombotic and <z:mp ids='MP_0001914'>bleeding</z:mp> effects of these antithrombotic agents </plain></SENT>
<SENT sid="3" pm="."><plain>We, therefore, evaluated the antithrombotic and <z:mp ids='MP_0001914'>bleeding</z:mp> profiles of dual and triple therapy with razaxaban, a direct factor Xa inhibitor, plus aspirin and/or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> in rabbit models of electrolytic injury-induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> and cuticle <z:mp ids='MP_0001914'>bleeding</z:mp> time, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Compounds were infused either IV or into the portal vein from 1 h before arterial injury or cuticle transection to the end of experiment </plain></SENT>
<SENT sid="5" pm="."><plain>Carotid blood flow was used as a marker of antithrombotic effect </plain></SENT>
<SENT sid="6" pm="."><plain>We first evaluated the antithrombotic potency of razaxaban, and examined its ex vivo effects on coagulation parameters to confirm its selectivity </plain></SENT>
<SENT sid="7" pm="."><plain>Antithrombotic ED(50) of razaxaban averaged 0.22 +/- 0.05 mg/kg/h (n = 6) </plain></SENT>
<SENT sid="8" pm="."><plain>Razaxaban at 3 mg/kg/h IV produced full antithrombotic efficacy, increased significantly ex vivo activated partial thromboplastin time and prothrombin time by 2.2 +/- 0.1- and 2.3 +/- 0.1-fold, respectively, and inhibited ex vivo factor Xa activity significantly by 91 +/- 5% (n = 6, P &lt; 0.05) without affecting ex vivo thrombin activity </plain></SENT>
<SENT sid="9" pm="."><plain>Razaxaban at concentrations up to 10 muM did not alter in vitro platelet aggregation responses to <z:chebi fb="13" ids="16761">ADP</z:chebi>, gamma-thrombin or collagen </plain></SENT>
<SENT sid="10" pm="."><plain>To identify additive or synergistic antithrombotic effects of the various combination therapies, we purposefully used marginally effective doses of razaxaban at 0.1 mg/kg/h, aspirin at 0.3 mg/kg/h and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> at 1 mg/kg/h </plain></SENT>
<SENT sid="11" pm="."><plain>Dual combination of threshold doses of razaxaban and aspirin or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> produced an enhanced antithrombotic effect without further increases in <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="12" pm="."><plain>When compared with dual therapy with aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (38 +/- 5% increase in blood flow), addition of razaxaban increased blood flow to 75 +/- 5% without additional <z:mp ids='MP_0001914'>bleeding</z:mp> time effects (n = 6/group, P &lt; 0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>In summary, razaxaban was an effective antithrombotic agent in a rabbit model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> for the prevention of occlusive <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> without excessive <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
</text></document>